Escherichia coli

大肠杆菌
  • 文章类型: Journal Article
    生物仿制药是从活生物体产生的或含有活成分的生物药物。它们具有相同的氨基酸序列和免疫原性。这些药物被认为是具有成本效益的,并且用于治疗癌症和其他内分泌紊乱。生物仿制药的主要目的是预测生物相似性,功效,和治疗费用;它们已获得食品和药物管理局(FDA)的批准,没有临床意义。它们涉及分析研究,以了解相似性和差异性。一家生物仿制药制造商建立了FDA批准的参考产品来评估生物相似性。下一代测序的贡献正在演变为研究器官肿瘤及其进展,其对癌症患者有影响力的治疗方法,以展示和靶向罕见突变。这项研究将有助于了解生物仿制药在胃肠道疾病中的未来前景,结直肠癌,和甲状腺癌。它们还有助于在临床实践中通过血液和液体活检靶向具有基本突变类别和药物原型的特定器官,细胞治疗,基因治疗,重组治疗性蛋白质,和个性化的药物。生物类似物衍生物如单克隆抗体如曲妥珠单抗和利妥昔单抗是用于癌症治疗的常见药物。大肠杆菌产生超过六种抗体或抗体衍生的蛋白质来治疗癌症,例如非格司亭,epoetinalfa,等等。
    Biosimilars are biological drugs created from living organisms or that contain living components. They share an identical amino-acid sequence and immunogenicity. These drugs are considered to be cost-effective and are utilized in the treatment of cancer and other endocrine disorders. The primary aim of biosimilars is to predict biosimilarity, efficacy, and treatment costs; they are approved by the Food and Drug Administration (FDA) and have no clinical implications. They involve analytical studies to understand the similarities and dissimilarities. A biosimilar manufacturer sets up FDA-approved reference products to evaluate biosimilarity. The contribution of next-generation sequencing is evolving to study the organ tumor and its progression with its impactful therapeutic approach on cancer patients to showcase and target rare mutations. The study shall help to understand the future perspectives of biosimilars for use in gastro-entero-logic diseases, colorectal cancer, and thyroid cancer. They also help target specific organs with essential mutational categories and drug prototypes in clinical practices with blood and liquid biopsy, cell treatment, gene therapy, recombinant therapeutic proteins, and personalized medications. Biosimilar derivatives such as monoclonal antibodies like trastuzumab and rituximab are common drugs used in cancer therapy. Escherichia coli produces more than six antibodies or antibody-derived proteins to treat cancer such as filgrastim, epoetin alfa, and so on.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:我们的目的是根据社区获得性大肠埃希菌尿路感染(UTI)患者在过去18个月内的抗生素暴露情况,量化个体对抗菌药物耐药的风险。
    方法:2015-2017年在两个中心前瞻性招募了法国患者。分离株对阿莫西林(AMX)的耐药性,阿莫西林-克拉维酸(AMC),第三代头孢菌素(3GC),甲氧苄啶-磺胺甲恶唑(TMP-SMX),氟喹诺酮类(FQ)和磷霉素(FOS)根据健康保险文件中记录的以前的类内和类间抗生素暴露进行分析.
    结果:在所分析的722例UTI病例(564例)中,有588例(81.4%)发现了以前的抗生素暴露。与远程暴露(UTI前18个月)相比,最近的暴露(UTI前3个月)对AMX的大肠杆菌耐药性具有更强的类内影响,AMC,FQ和TMP-SMX,相应的调整后赔率比[95%置信区间]为1.63[1.20-2.21],1.59[1.02-2.48],3.01[1.90-4.77],和2.60[1.75-3.87]。AMX,FQ,TMP-SMX也表现出显著的类间影响。对3GC的抗性与组内暴露没有显着相关(调整后的OR:0.88[0.41-1.90])。FOS抗性显著低(0.4%)。耐药性风险降至10%以下所需的无抗生素期持续时间,在UTI中经验使用的阈值,被建模为3GC<1个月,AMX和TMP-SMX>18个月,AMC(5.2个月[2.3至>18])和FQ(17.4个月[7.4至>18])不确定。
    结论:引起UTI的E.coli的耐药性部分可以通过以前的个人抗生素使用来预测。
    OBJECTIVE: We aimed to quantify the individual risk of antimicrobial resistance among patients with community-acquired Escherichia coli urinary tract infection (UTI) according to their antibiotic exposure over the previous 18 months.
    METHODS: French patients were prospectively recruited in two centers in 2015-2017. Resistance of isolates to amoxicillin (AMX), amoxicillin-clavulanate (AMC), third-generation cephalosporins (3GC), trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolones (FQ) and fosfomycin (FOS) was analysed according to previous intra-class and inter-class antibiotic exposure documented in health insurance files.
    RESULTS: Previous antibiotic exposure was found in 588 (81.4 %) of the 722 UTI cases analysed (564 patients). Recent exposure (three months before UTI) was associated with stronger intra-class impact on E. coli resistance compared to remote exposure (18 months before UTI) for AMX, AMC, FQ and TMP-SMX, with respective adjusted odds ratios [95 % confidence interval] of 1.63 [1.20-2.21], 1.59 [1.02-2.48], 3.01 [1.90-4.77], and 2.60 [1.75-3.87]. AMX, FQ, and TMP-SMX also showed significant inter-class impact. Resistance to 3GC was not significantly associated with intraclass exposure (adjusted OR: 0.88 [0.41-1.90]). FOS resistance was remarkably low (0.4 %). Duration of the antibiotic-free period required for resistance risk to drop below 10 %, the threshold for empirical use in UTI, was modelled as < 1 month for 3GC, >18 months for AMX and TMP-SMX and uncertain for AMC (5.2 months [2.3 to > 18]) and FQ (17.4 months [7.4 to > 18]).
    CONCLUSIONS: Resistance of E. coli causing UTI is partially predicted by previous personal antibiotic delivery.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    这篇综述强调了传统废水处理厂(WWTP)在有效去除新兴污染物(CEC)方面所面临的局限性,重金属(HMs),和大肠杆菌(E.大肠杆菌)。这强调了当前处理方法的局限性,并倡导了提高去除效率的创新方法。通过遵循PRISMA准则,该研究系统地回顾了有关废水处理设施中这些污染物的检测和治理的相关文献。传统的废水处理厂努力消除CEC,HMs,和大肠杆菌由于它们的体积小,持久性,和复杂的性质。该评论建议使用先进的三级工艺升级污水处理厂,以显着提高污染物的去除效果。这需要具有成本效益的治疗参数和标准化的评估技术,以提高MPP在WWTP和WRRF中的命运。建议将质量平衡模型研究的见解整合到WWTP中,以克服建模挑战并确保模型可靠性。总之,这篇综述强调了迫切需要改进废水处理工艺,以减轻痕量人为生物标志物对环境的影响。今后的工作重点应该是进行全面的研究,实施先进的治疗方法,并优化污水处理厂和WRRF的管理实践。
    This review highlights the limitations faced by conventional wastewater treatment plants (WWTPs) in effectively removing contaminants of emerging concern (CECs), heavy metals (HMs), and Escherichia coli (E. coli). This emphasises the limitations of current treatment methods and advocates for innovative approaches to enhance the removal efficiency. By following the PRISMA guidelines, the study systematically reviewed relevant literature on detecting and remedying these pollutants in wastewater treatment facilities. Conventional wastewater treatment plants struggle to eliminate CECs, HMs, and E. coli owing to their small size, persistence, and complex nature. The review suggests upgrading WWTPs with advanced tertiary processes to significantly improve contaminant removal. This calls for cost-effective treatment parameters and standardised assessment techniques to enhance the fate of MPs in WWTPs and WRRFs. It recommends integrating insights from mass-balance model studies on MPs in WWTP to overcome modelling challenges and ensure model reliability. In conclusion, this review underscores the urgent need for advancements in wastewater treatment processes to mitigate the environmental impact of trace anthropogenic biomarkers. Future efforts should focus on conducting comprehensive studies, implementing advanced treatment methods, and optimising management practices in WWTPs and WRRFs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    本研究旨在基于网络药理学方法分析头花何首乌(PC)抑制大肠杆菌的有效成分,并预测其分子作用机制。从TCMSP数据库收集PC化合物和靶标,瑞士目标预测,和文学。使用GeneCards数据库搜索大肠杆菌靶标。取大肠杆菌的靶标与PC活性成份的靶标为交点,获得了相交的靶标。将得到的重叠靶标上传到STRING数据库,构建大肠杆菌靶标抑制的蛋白质相互作用网络图。获得了PC对大肠杆菌抑制作用的关键靶标。基因本体论和京都百科全书基因和基因组途径富集分析通过将关键靶标上传到DAVID数据库中进行。结果表明,PC有50个抑制大肠杆菌的靶标。其中,有五个核心目标,主要包括AKT1、TNF、EGFR,JUN,和ESR1。共获得196个基因本体功能分析结果和126个京都百科全书基因和基因组途径富集分析结果。这些包括细胞对镉离子的反应,细胞对活性氧的反应,癌症的通路,前列腺癌,和PI3K-Akt信号通路。分子对接结果表明,叶黄素,Hirsutin,Flazin,PC中的鞣花酸对靶基因AKT1、TNF、MAPK3和EGFR。PC通过多靶点、多途径发挥对大肠杆菌的抑制作用,为PC作为老药的新用途提供了新的依据。
    This study aims to analyze the effective components of Polygonum capitatum (PC) inhibiting Escherichia coli based on network pharmacology methods and predict its molecular mechanism of action. PC compounds and targets were collected from the TCMSP database, Swiss Target Prediction, and the literature. E coli targets were searched using the GeneCards database. The targets of E coli and the targets of the active ingredients of PC were taken as intersections to obtain the intersecting targets. The resulting overlapping targets were uploaded to the STRING database to construct the protein interaction network diagram of E coli target inhibition. The key targets for the inhibitory effect of PC on E coli were obtained. Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed by uploading key targets into the DAVID database. The results showed that there were 50 targets for PC to inhibit E coli. Among them, there are 5 core targets, mainly including AKT1, TNF, EGFR, JUN, and ESR1. A total of 196 gene ontology functional analysis results and 126 Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis results were obtained. These include cellular response to cadmium-ion, cellular response to reactive oxygen species, pathways in cancer, prostate cancer, and PI3K-Akt signaling pathway. Molecular docking results indicate that Lutedin, Hirsutin, Flazin, and Ellagic acid in PC have high affinity for the target genes AKT1, TNF, MAPK3 and EGFR. PC exerts its inhibitory effect on E coli through multi-targets and multi-pathways, which provides a new basis for the new use of PC as an old medicine.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • DOI:
    文章类型: Journal Article
    BACKGROUND: According to the World Health Organization, antimicrobial resistance (AMR) is a silent global pandemic that plagues everyone. It makes therapy of infectious diseases more difficult and eventually increases morbidity and mortality.
    OBJECTIVE: The purpose of this work is to examine existing data on plasmid-mediated quinolone resistance (PMQR), to assess the prevalence of PMQR genes in Enterobacterales, and to determine any knowledge gaps from sub-Saharan Africa.
    METHODS: The Preferred Reporting Items of Systematic Reviews and Meta-analyses (PRISMA) standard was followed when conducting this systematic review. The main internet databases examined for pertinent publications were PubMed, Google Scholar, and Ajol. A set of qualifying criteria were used to evaluate the qualified articles. Using the eligibility criteria, 56 full-text articles were chosen for screening.
    RESULTS: Thirty-two (32) articles with the majority originating from West and North Africa and only one article reporting a study carried out in Central Africa were selected for this review. Escherichia coli and Ciprofloxacin were the most reported Enterobacterales and Quinolone respectively. The PMQR genes include qnr (qnrA,qnrB, qnrC, qnrD, and qnrS), aac (6\') Ib, aac (6\') Ib-cr, oqxAB and qepA gene. The most prevalent PMQR gene is the aac (6\') Ib-cr gene (32%) followed by qnrS (26%).
    CONCLUSIONS: This study highlighted the requirement for an efficient antimicrobial resistance surveillance system in the continent and revealed a significant incidence of PMQR genes.
    BACKGROUND: Selon l\'Organisation mondiale de la santé, la résistance aux antimicrobiens (RAM) est une pandémie mondiale silencieuse qui touche tout le monde. Elle rend le traitement des maladies infectieuses plus difficile et finit par augmenter la morbidité et la mortalité.
    OBJECTIVE: L\'objectif de ce travail est d\'examiner les données existantes sur la résistance plasmidique aux quinolones (PMQR), d\'évaluer la prévalence des gènes PMQR chez les Enterobacterales et de déterminer d\'éventuelles lacunes de connaissances en Afrique subsaharienne.
    UNASSIGNED: La norme Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) a été suivie lors de la réalisation de cette revue systématique. Les principales bases de données Internet examinées pour des publications pertinentes étaient PubMed, Google Scholar et Ajol. Un ensemble de critères d\'admissibilité a été utilisé pour évaluer les articles qualifiés. En utilisant les critères d\'éligibilité, 56 articles en texte intégral ont été choisis pour le dépistage.
    UNASSIGNED: Trente-deux (32) articles, dont la majorité provient d\'Afrique de l\'Ouest et du Nord, et un seul article rapportant une étude menée en Afrique centrale, ont été sélectionnés pour cette revue. Escherichia coli et la ciprofloxacine étaient les Enterobacterales et les quinolones les plus signalées respectivement. Les gènes PMQR comprennent les gènes qnr (qnrA, qnrB, qnrC, qnrD et qnrS), aac (6 \') Ib, aac (6 \') Ib-cr, oqxAB et qepA. Le gène PMQR le plus prévalent est le gène aac (6 \') Ib-cr (32 %), suivi de qnrS (26 %).
    CONCLUSIONS: Cette étude a souligné la nécessité d\'un système efficace de surveillance de la résistance aux antimicrobiens sur le continen`t et a révélé une incidence significative des gènes PMQR.
    UNASSIGNED: Enterobacterales, Escherichia coli, Quinolone, Ciprofloxacine, PMQR, \"aac(6\')-Ib\", \"aac(6\')-Ib-cr\", \"qnr\", \"qepA\", \"oqxAB\", \"résistance aux antibiotiques\".
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    大肠杆菌中抗生素耐药性的传播对全球公共卫生构成重大威胁。这篇综述提供了大肠杆菌在开发抗生素耐药性中所采用的多种机制的全面更新。我们主要关注大肠杆菌的致病型(例如,尿路致病性大肠杆菌),并研究赋予耐药性的遗传决定因素和分子途径,揭示了特征明确和最近发现的机制。最普遍的机制仍然是通过水平基因转移获得抗性基因,由移动遗传元件如质粒和转座子促进。我们讨论了超广谱β-内酰胺酶(ESBLs)和碳青霉烯酶在赋予β-内酰胺抗生素耐药性中的作用,这在临床实践中仍然至关重要。审查涵盖了关键的抵抗机制,包括:1)外排泵和孔蛋白突变,介导对广谱抗生素的抗性,包括氟喹诺酮类和氨基糖苷类;2)大肠杆菌采用的适应性策略,包括生物膜的形成,持久细胞的形成,和激活应激反应系统,承受抗生素压力;3)监管系统在协调耐药机制中的作用,提供对治疗干预的潜在目标的见解。了解大肠杆菌中复杂的抗生素耐药机制网络对于制定有效的策略来应对这种日益严重的公共卫生危机至关重要。通过澄清这些机制,我们的目标是为创新治疗方法的设计和审慎抗生素管理实践的实施铺平道路,以保持当前抗生素的功效,并确保医疗保健的可持续未来。
    The dissemination of antibiotic resistance in Escherichia coli poses a significant threat to public health worldwide. This review provides a comprehensive update on the diverse mechanisms employed by E. coli in developing resistance to antibiotics. We primarily focus on pathotypes of E. coli (e.g., uropathogenic E. coli) and investigate the genetic determinants and molecular pathways that confer resistance, shedding light on both well-characterized and recently discovered mechanisms. The most prevalent mechanism continues to be the acquisition of resistance genes through horizontal gene transfer, facilitated by mobile genetic elements such as plasmids and transposons. We discuss the role of extended-spectrum β-lactamases (ESBLs) and carbapenemases in conferring resistance to β-lactam antibiotics, which remain vital in clinical practice. The review covers the key resistant mechanisms, including: 1) Efflux pumps and porin mutations that mediate resistance to a broad spectrum of antibiotics, including fluoroquinolones and aminoglycosides; 2) adaptive strategies employed by E. coli, including biofilm formation, persister cell formation, and the activation of stress response systems, to withstand antibiotic pressure; and 3) the role of regulatory systems in coordinating resistance mechanisms, providing insights into potential targets for therapeutic interventions. Understanding the intricate network of antibiotic resistance mechanisms in E. coli is crucial for the development of effective strategies to combat this growing public health crisis. By clarifying these mechanisms, we aim to pave the way for the design of innovative therapeutic approaches and the implementation of prudent antibiotic stewardship practices to preserve the efficacy of current antibiotics and ensure a sustainable future for healthcare.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Meta-Analysis
    背景:本系统综述旨在确定尼泊尔尿液样本中产生超广谱β-内酰胺酶的大肠杆菌(ESBL-EC)的抗菌耐药性模式。
    方法:进行了系统文献综述,以查找2012年1月至2022年12月期间发表的所有报告ESBL-EC的尿液样本中的文章。进行Egger加权回归分析以评估发表偏倚。由于研究之间的显着异质性,使用随机效应模型来计算合并的患病率和相应的95%置信区间。使用Pearson相关系数确定了多药耐药性与大肠杆菌中ESBL产生之间的相关性强度。使用R语言4.2.2分析数据。软件。
    结果:发现尿液样本中大肠杆菌的合并患病率为14%(95%CI,11-18),而ESBL大肠杆菌和MDR大肠杆菌的总体合并患病率分别为30%(95%CI,20-42)和70%(95%CI,38-90)。在大肠杆菌分离株中,ESBL生产与MDR之间存在0.99(95%CI,0.89-1.0)的强正相关。亚胺培南是对抗ESBL-E的首选药物。尿液标本中的大肠杆菌。
    结论:我们的分析显示,尼泊尔的ESBL-EC和MDR-EC总体负担相当高。同样,该研究还推断尿液样本中ESBL-EC的抗生素耐药模式有增加的趋势.
    BACKGROUND: This systematic review aimed to determine the antimicrobial resistance pattern of the extended-spectrum β-lactamases producing Escherichia coli (ESBL-EC) in urine samples in Nepal.
    METHODS: Systematic literature review was conducted to locate all articles reporting ESBL-EC in urine samples published between January 2012 to December 2022. The Egger\'s weighted regression analysis was done to assess the publication bias. A random-effects model was used to calculate the pooled prevalence and corresponding 95% confidence interval due to significant between-study heterogeneity. The strength of correlation between multidrug resistance and ESBL production in E.coli strains was determined using Pearson\'s correlation coefficient. The data were analyzed using R-language 4.2.2. software.
    RESULTS: The combined prevalence of E.coli in urine samples was found to be 14 % (95% CI, 11-18), while the overall pooled prevalence of ESBL E.coli and MDR E.coli were 30% (95% CI, 20-42) and 70% (95% CI, 38-90) respectively. A strong positive correlation of 0.99 (95% CI, 0.89-1.0) was found between ESBL production and MDR among E.coli isolates. Imipenem was the drug of choice against ESBL-E.coli in urine specimens.
    CONCLUSIONS: Our analyses showed the overall ESBL-EC and MDR-EC burden in Nepal is considerably high. Likewise, the study also infers an increasing trend of antibiotic resistance pattern of ESBL-EC in urine samples.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    产生碳青霉烯酶的革兰氏阴性菌(CP-GNB)感染威胁公众健康,死亡率高,发病率和治疗费用。尽管澳大利亚的频率仍然很低(2022年报告的CP-GNB感染总数为907),blaIMP-4在许多州都建立了低水平的地方性。在澳大利亚产生碳青霉烯酶的肠杆菌分离株中,单独的亚胺酶金属-β-内酰胺酶类型占所有碳青霉烯酶的一半以上,特别是阴沟肠杆菌。新德里金属-β-内酰胺酶占澳大利亚所有碳青霉烯酶的近25%,主要在大肠杆菌中被鉴定。OXA-48样碳青霉烯酶包括几乎所有碳青霉烯酶的10%,并且主要见于肺炎克雷伯菌和大肠杆菌中。尽管肺炎克雷伯菌碳青霉烯酶型碳青霉烯酶在澳大利亚很少见,一些地方爆发了。澳大利亚大多数耐碳青霉烯(CR)铜绿假单胞菌菌株不产生碳青霉烯酶。最后,OXA-23样碳青霉烯酶在澳大利亚的CR-鲍曼不动杆菌菌株中绝大多数为阳性。CR-GNB感染的治疗挑战医生。美国食品和药物管理局批准的10种新的抗生素对至少一些CR-GNB感染有效,只有三个被批准在澳大利亚使用。在这种情况下,在澳大利亚,对可用于治疗CR-GNB感染的新型抗菌药物的需求仍未满足。以及对新机制的迫切要求,将抗生素销售与其可用性“脱钩”。在这篇叙述性评论中,我们旨在概述澳大利亚碳青霉烯耐药的流行病学和临床意义,因为它与肠杆菌有关,铜绿假单胞菌和鲍曼不动杆菌。
    Carbapenemase-producing gram-negative bacteria (CP-GNB) infections threaten public health with high mortality, morbidity and treatment costs. Although frequencies remain low in Australia (total number of CP-GNB infections reported was 907 in 2022), blaIMP-4 has established low levels of endemicity in many states. Imipenemase metallo-β-lactamase types alone accounted for more than half of all carbapenemases in carbapenemase-producing Enterobacterales isolates in Australia, particularly in Enterobacter cloacae complex. New Delhi metallo-β-lactamase constitutes almost 25% of all carbapenemases in Australia and was identified predominantly in Escherichia coli. The OXA-48-like carbapenemases include almost 10% of all carbapenemases and are mainly seen in Klebsiella pneumoniae and E. coli. Although K. pneumoniae carbapenemase-type carbapenemases are rare in Australia, some local outbreaks have occurred. Most carbapenem-resistant (CR) Pseudomonas aeruginosa strains in Australia do not produce carbapenemases. Finally, OXA-23-like carbapenemases are overwhelmingly positive in CR-Acinetobacter baumannii strains in Australia. Treatment of CR-GNB infections challenges physicians. Of 10 new antibiotics active against at least some CR-GNB infections that are approved by the US Food and Drug Administration, just three are approved for use in Australia. In this context, there is still an unmet need for novel antibacterials that can be used for the treatment of CR-GNB infections in Australia, as well as a pressing requirement for new mechanisms to \'de-link\' antibiotic sales from their availability. In this narrative review, we aim to overview the epidemiology and clinical significance of carbapenem resistance in Australia as it pertains to Enterobacterales, P. aeruginosa and A. baumannii.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    确定环境水中细菌病原体和抗菌素耐药性(AMR)的标准化评估方法可以提高监测和收集数据的质量,支持全球监测工作,加强对环境水源的认识。我们进行了系统综述,以收集和综合现有文献,确定了评估水中细菌粪便指标和病原体的患病率和丰度的方法,以监测细菌病原体和AMR。经过质量筛选,从15个数据库中确定了175种独特的出版物,并提取数据进行分析。这篇综述确定了最常见和最可靠的方法,和用于从地表水源分离目标生物的培养基,总结了方法论趋势,并认识到知识差距。在美国和全球建立监测水中细菌病原体和AMR的标准化方法时,本综述中提供的信息将很有用。
    Identification of methods for the standardized assessment of bacterial pathogens and antimicrobial resistance (AMR) in environmental water can improve the quality of monitoring and data collected, support global surveillance efforts, and enhance the understanding of environmental water sources. We conducted a systematic review to assemble and synthesize available literature that identified methods for assessment of prevalence and abundance of bacterial fecal indicators and pathogens in water for the purposes of monitoring bacterial pathogens and AMR. After screening for quality, 175 unique publications were identified from 15 databases, and data were extracted for analysis. This review identifies the most common and robust methods, and media used to isolate target organisms from surface water sources, summarizes methodological trends, and recognizes knowledge gaps. The information presented in this review will be useful when establishing standardized methods for monitoring bacterial pathogens and AMR in water in the United States and globally.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:尿路感染(UTI)是最常见的医院感染类型,并且由于困难和频繁复发而导致严重的健康问题。今天,替代方法,如声动力疗法(SDT),在许多国家,光动力疗法(PDT)和草药材料用于治疗UTI等感染。
    方法:我们对生物医学数据库进行了搜索(谷歌学者,Scopus,PubMed,和WebofSciences)确定2008-2023年的相关研究。
    结果:SDT旨在使用超声波激活声敏剂,通过提高活性氧(ROS)引起生物效应。当细菌暴露于ROS时,发生了几个重要的影响:氧化损伤,DNA损伤,蛋白质功能障碍等.使用草药的SDT显着降低了菌落形成单位的数量和对肺炎克雷伯菌和大肠杆菌的杀菌活性。PDT是一种很有前途的治疗癌症和微生物感染,结合光敏剂,光和组织分子氧。它涉及光敏剂,光源,和氧气,变化会影响微生物结合和杀菌活性。影响抗菌性能的因素包括植物类型,生长条件,收获,和处理。这篇综述强调了声动力学的最新进展,光动力,草药,和基于生物材料的方法治疗大肠杆菌感染。
    结论:这些替代疗法为解决尿路感染提供了令人兴奋的前景,尤其是在传统抗生素治疗可能不太有效的情况下。需要进一步的研究和临床研究,以充分探索这些创新治疗方式在对抗尿路感染和改善患者预后方面的潜力。
    BACKGROUND: Urinary tract infections (UTIs) are the most common type of nosocomial infection and severe health issues because of the difficulties and frequent recurrence. Today, alternative methods such as sonodynamic therapy (SDT), photodynamic therapy (PDT) and herbal materials use for treating infections like UTI in many countries.
    METHODS: We conducted searches of the biomedical databases (Google Scholar, Scopus, PubMed, and Web of sciences) to identify related studies from 2008 to 2023.
    RESULTS: SDT aims to use ultrasound to activate a sonosensitizer, which causes a biological effect by raising reactive oxygen species (ROS). When bacteria are exposed to ROS, several important effects occur: oxidative damage, DNA damage, protein dysfunction etc. SDT with herbal medicine significantly reduced the number of colony-forming units and bactericidal activity for Klebsiella pneumonia and E. coli. PDT is a promising treatment for cancer and microbial infections, combining a photosensitiser, light and tissue molecular oxygen. It involves a photosensitizer, light source, and oxygen, with variations affecting microbial binding and bactericidal activity. Factors affecting antibacterial properties include plant type, growing conditions, harvesting, and processing. This review highlights the recent advancements in sonodynamic, photodynamic, herbal, and bio-material-based approaches in the treatment of E. coli infections.
    CONCLUSIONS: These alternative therapies offer exciting prospects for addressing UTIs, especially in cases where traditional antibiotic treatments may be less effective. Further research and clinical studies are warranted to fully explore the potential of these innovative treatment modalities in combating UTIs and improving patient outcomes.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号